BCR and acute promyelocytic leukemia: Acute promyelocytic leukemia (APL) molecular diagnosis and minimal residual disease (MRD) monitoring are currently based on bcr1, bcr2 or bcr3 fusion transcript detection, depending on the DNA breakpoint21,22.